Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry

on behalf of the ECMM-CAPA Study Group

doi:10.1007/s00134-021-06471-6

Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry

on behalf of the ECMM-CAPA Study Group

Department of Pathology and Laboratory Medicine, Medical College, Pakistan

Research output: Contribution to journal › Letter › peer-review

40 Citations (Scopus)

Original language	English
Pages (from-to)	1158-1160
Number of pages	3
Journal	Intensive Care Medicine
Volume	47
Issue number	10
DOIs	https://doi.org/10.1007/s00134-021-06471-6
Publication status	Published - Oct 2021

Access to Document

10.1007/s00134-021-06471-6

Cite this

@article{15394c4421c14fdd825e86d7ec4f1c8d,

title = "Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry",

author = "{on behalf of the ECMM-CAPA Study Group} and Juergen Prattes and Joost Wauters and Giacobbe, {Daniele Roberto} and Katrien Lagrou and Martin Hoenigl and Philipp Koehler and Jon Salmanton-Garc{\'i}a and Riina Rautemaa-Richardson and Stefan Hatzl and Johan Maertens and Yves Debaveye and Marc Bourgeois and Marijke Reynders and Lynn Rutsaert and {Van Regenmortel}, Niels and Piet Lormans and Simon Feys and Reisinger, {Alexander Christian} and Cornely, {Oliver A.} and Tobias Lahmer and Maricela Valerio and Laurence Delhaes and Kauser Jabeen and Joerg Steinmann and Mathilde Chamula and Matteo Bassetti",

note = "Funding Information: JP has received personal fees from Gilead Sciences and Pfizer, research funding from MSD and is stoke holder of AbbVie Inc and Novo Nordisk. JW reports grants and personal fees from Gilead and Pfizer: investigator-initiated grants, personal fees and also on-financial support from MSD. DRG reports an unconditional grant from Correvio Italia and a grant for his institution by Pfizer Inc. KL received consultancy fees from SMB Laboratories Brussels, MSD and Gilead, travel support from Pfizer, speaker fees from FUJIFILM WAKO, Pfizer and Gilead and a service fee from Thermo fisher Scientific. MH received research funding from Gilead Sciences, Astellas, Scynexis, F2G and Pfizer. Funding Information: MH is supported by NIH and investigator initiated grants from Astellas, Gilead and Pfizer. No specific funding obtained for this study. ",

year = "2021",

month = oct,

doi = "10.1007/s00134-021-06471-6",

language = "English",

volume = "47",

pages = "1158--1160",

journal = "Intensive Care Medicine",

issn = "0342-4642",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients

T2 - results from a European confederation of medical mycology registry

AU - on behalf of the ECMM-CAPA Study Group

AU - Prattes, Juergen

AU - Wauters, Joost

AU - Giacobbe, Daniele Roberto

AU - Lagrou, Katrien

AU - Hoenigl, Martin

AU - Koehler, Philipp

AU - Salmanton-García, Jon

AU - Rautemaa-Richardson, Riina

AU - Hatzl, Stefan

AU - Maertens, Johan

AU - Debaveye, Yves

AU - Bourgeois, Marc

AU - Reynders, Marijke

AU - Rutsaert, Lynn

AU - Van Regenmortel, Niels

AU - Lormans, Piet

AU - Feys, Simon

AU - Reisinger, Alexander Christian

AU - Cornely, Oliver A.

AU - Lahmer, Tobias

AU - Valerio, Maricela

AU - Delhaes, Laurence

AU - Jabeen, Kauser

AU - Steinmann, Joerg

AU - Chamula, Mathilde

AU - Bassetti, Matteo

N1 - Funding Information: JP has received personal fees from Gilead Sciences and Pfizer, research funding from MSD and is stoke holder of AbbVie Inc and Novo Nordisk. JW reports grants and personal fees from Gilead and Pfizer: investigator-initiated grants, personal fees and also on-financial support from MSD. DRG reports an unconditional grant from Correvio Italia and a grant for his institution by Pfizer Inc. KL received consultancy fees from SMB Laboratories Brussels, MSD and Gilead, travel support from Pfizer, speaker fees from FUJIFILM WAKO, Pfizer and Gilead and a service fee from Thermo fisher Scientific. MH received research funding from Gilead Sciences, Astellas, Scynexis, F2G and Pfizer. Funding Information: MH is supported by NIH and investigator initiated grants from Astellas, Gilead and Pfizer. No specific funding obtained for this study.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85110649155&partnerID=8YFLogxK

U2 - 10.1007/s00134-021-06471-6

DO - 10.1007/s00134-021-06471-6

M3 - Letter

C2 - 34269853

AN - SCOPUS:85110649155

SN - 0342-4642

VL - 47

SP - 1158

EP - 1160

JO - Intensive Care Medicine

JF - Intensive Care Medicine

IS - 10

ER -

Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry

Access to Document

Other files and links

Cite this